Celladon to suspend development of gene-therapy drug

June 26, 2015 10:50 AM

9 0

Celladon Corp said it would suspend further development of its gene-therapy drug for heart failure, months after the treatment failed a mid-stage trial.

The company's shares fell 34 percent to $1.34 in premarket trading. Celladon also announced a second reduction in its workforce on Friday.

Also read: Sales of new homes rose 3.1 percent in September

Read more

To category page